News

In an interview with HCPLive, Sunny Rai, PhD, shed light on a new study regarding how an AI model failed to detect depression in Black individuals.

Using the National Institutes of Health Toolbox Cognition Battery, results showed greater cognitive dysfunction across certain domains based on sex and CKD stage.

Benjamin Smith, DMSc, PA-C, discusses integrative rheumatoid arthritis treatment guidelines.

Anemia and iron deficiency are prevalent in heart failure with mildly reduced ejection fraction and may worsen mortality and rehospitalization outcomes.

This analysis compared the efficacy of a 5 mg daily dose of oral minoxidil to topical minoxidil, 5%, among male alopecia patients.

A new study showed secukinumab was not superior to Sandoz adalimumab (SDZ-ADL; TNF inhibitor) in terms of similar low rates of radiographic progression and safety profiles.

A retrospective analysis of EHR data from ACC.24 provides insight into the effects of ARNI relative to ACEi/ARB in patients with newly diagnosed heart failure and an LVEF greater than 40%.

The proposed insulin glargine biosimilar (Basalin) showed comparable immunogenicity, efficacy, and safety to the originator (Lantus) in a phase 3 equivalence trial.

Jinny Tavee, MD, explains the potential neurological complications of sarcoidosis, an autoimmune disease that affects multiple systems.

Treatment with intravenous iron therapy proves more efficacious than oral or no iron therapy in improving hemoglobin in pediatric patients admitted with IBD and IDA.

Tracy Frech, MD, MSCI, explains what rheumatologists need to know about preventing and management digital ischemia.

A notable overrepresentation of women was observed among individuals with ABCA4-associated retinopathy carrying a mild variant with reduced penetrance.

These data highlight guselkumab’s impact on psoriasis patients’ symptoms and HRQoL, as well as on sexual impairment and perceptions of stigmatization.

Safia Chatur, MD, discusses the results of a PARADIGM-HF analysis at ACC.24 examining the effects of ARNI use across the updated 2024 KDIGO Risk Classifications.

A study found MRI treat-to-target strategy does not help bring RA patients to remission, even when also targeting the absence of osteitis alongside clinical remission.

Although overall engagement in the HCV care cascade improved after the introduction of DAAs, vulnerable subgroups still received less testing and treatment.

These data highlight the frequency of adverse events with narrow-band UVB phototherapy and concomitant therapy.

Ankeet Bhatt, MD, MBA, discusses a NUDGE-FLU analysis from ACC.24 examining effect of the CV gain-framed nudge in patients with and without history of AMI.

A new study found extending postpartum Medicaid from 60 days to 12 months is linked to new mothers being more likely to seek mental health care for perinatal mood and anxiety disorders.

Results showed poorly controlled HbA1C increased the risk of elevated ALT levels in children and adolescents with type 1 diabetes, suggesting an important link to MASLD.

Ahmad Masri, MD, MS, discusses a study from ACC.24 examining trends in incidence and outcomes of emergency department visits related to hypertrophic cardiomyopathy from 2006 to 2019.

In a nationwide study of an adult SCD population, the risk of mortality increased with the number of HVOCs in the year before death.

Without controlling for the severity of symptoms, patients with either fibromyalgia or RA performed worse when compared with controls in terms of cognitive domains including verbal memory, visual memory, and strategic planning.

Sara Saberi, MD, discusses 1-year data from a cohort of 46 patients within the FOREST-HCM trial at ACC.24.

The geographic distribution of pediatric optometrists and ophthalmologists substantially overlaps in the US in 2023.

Despite these conclusions, this meta-analysis also showed that those receiving PDE4 inhibitors were the least likely to report adverse events.

A new study provides insight into the effectiveness of IFX-dyyb in a real-world US population of RA patients, showing how the biosimilar compares to other treatments.

RUBY-3 findings support povetacicept’s ability to induce remission, reduce UPCR, stabilize renal function, and resolve hematuria in patients with IgAN.

The FDA approval of benralizumab for patients ages 6 to 11 with asthma follows the conclusions of the phase 3 TATE study.

Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.